Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Therapies for Triple-Negative Breast Cancer
Tomás G. Lyons
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 11
Closed Access | Times Cited: 282

Showing 1-25 of 282 citing articles:

Breast Cancer Treatments: Updates and New Challenges
Anna Burguin, Caroline Diorio, Francine Durocher
Journal of Personalized Medicine (2021) Vol. 11, Iss. 8, pp. 808-808
Open Access | Times Cited: 273
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 114
Understanding and targeting resistance mechanisms in cancer
Zi‐Ning Lei, Tian Qin, Qiu‐Xu Teng, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 107
Live Macrophage-Delivered Doxorubicin-Loaded Liposomes Effectively Treat Triple-Negative Breast Cancer
Lan Yang, Yongshun Zhang, Yu Zhang, et al.
ACS Nano (2022) Vol. 16, Iss. 6, pp. 9799-9809
Closed Access | Times Cited: 81
Tunable Multivalent Aptamer-Based DNA Nanostructures To Regulate Multiheteroreceptor-Mediated Tumor Recognition
Xiaoxue Hu, Hongli Chi, Xiaoyi Fu, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 4, pp. 2514-2523
Closed Access | Times Cited: 21
MRI‐Guided Tumor Therapy Based on Synergy of Ferroptosis, Immunosuppression Reversal and Disulfidptosis
Shuai Guo, Zongheng Li, Ruilong Zhou, et al.
Small (2024) Vol. 20, Iss. 29
Closed Access | Times Cited: 16
Long Non-Coding RNA HOTAIR in Breast Cancer Therapy
Monica Cantile, Maurizio Di Bonito, Margherita Cerrone, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1197-1197
Open Access | Times Cited: 92
Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions
Minru Liao, Jin Zhang, Guan Wang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2382-2418
Closed Access | Times Cited: 83
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 557-565
Closed Access | Times Cited: 80
Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
Meghana Manjunath, Bibha Choudhary
Oncology Letters (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 74
Cancer stem cells in TNBC
Zhan Hua, Jason White, Jianjun Zhou
Seminars in Cancer Biology (2021) Vol. 82, pp. 26-34
Closed Access | Times Cited: 59
Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells
Jessica E. Pullan, Kaitlin M. Dailey, Sangeeta Bhallamudi, et al.
ACS Applied Bio Materials (2022) Vol. 5, Iss. 5, pp. 2163-2175
Open Access | Times Cited: 43
CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer
Tianyi Cheng, Yingyi Wu, Zhiyu Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
Cristian Arriaga-Canon, Laura Contreras‐Espinosa, Sergio Aguilar-Villanueva, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7426-7426
Open Access | Times Cited: 37
Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
Boya Lu, Elango Natarajan, Hanumantha Rao Balaji Raghavendran, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 36
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer
Xiaoxiang Sun, Huanyin Tang, Yu Chen, et al.
Nature Cancer (2023) Vol. 4, Iss. 5, pp. 716-733
Closed Access | Times Cited: 27
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer
Siyu Guo, Xinkui Liu, Jingyuan Zhang, et al.
Computers in Biology and Medicine (2023) Vol. 161, pp. 107066-107066
Open Access | Times Cited: 23
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Heba Alkhatib, Jason E. Conage‐Pough, Sangita Roy Chowdhury, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
MiRNA and mRNA-Controlled Double-Cascaded Amplifying Circuit Nanosensor for Accurate Discrimination of Breast Cancers in Living Cells, Animals, and Organoids
Huihui Yang, Dong Chen, Yanfei Zhang, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 10, pp. 4154-4162
Closed Access | Times Cited: 9
Triple negative breast cancer in the era of miRNA
Hussein Sabit, Emre Çevik, Hüseyin Tombuloğlu, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 157, pp. 103196-103196
Closed Access | Times Cited: 52
Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope
Peter J. Choi, Thomas Park, Elizabeth Cooper, et al.
Bioconjugate Chemistry (2020) Vol. 31, Iss. 7, pp. 1724-1739
Closed Access | Times Cited: 51
Discovery of precision targeting EZH2 degraders for triple-negative breast cancer
Cheng Wang, Xinye Chen, Xingchen Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114462-114462
Closed Access | Times Cited: 37
Estrogens, Cancer and Immunity
Izabela Orzołek, Jan Sobieraj, Joanna Domagała‐Kulawik
Cancers (2022) Vol. 14, Iss. 9, pp. 2265-2265
Open Access | Times Cited: 30
ICAM1 promotes bone metastasis via integrin‐mediated TGF‐β/EMT signaling in triple‐negative breast cancer
Mingcang Chen, Chunyu Wu, Zhengwei Fu, et al.
Cancer Science (2022) Vol. 113, Iss. 11, pp. 3751-3765
Open Access | Times Cited: 29
Phytotherapeutic applications of alkaloids in treating breast cancer
Shailima Rampogu, Thananjeyan Balasubramaniyam, Joon‐Hwa Lee
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113760-113760
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top